What Is Syndax Pharmaceuticals, Inc. (SNDX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Syndax Pharmaceuticals, Inc.'s intrinsic value is estimated at $5.68, suggesting the stock is overvalued at its current price of $23.52. With 8 out of 9 models flagging downside (-75.9% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: PWERM targets $23.14 (-1.6%), versus Regime Cross at $0.01 (-100.0%). This +98.3% range highlights the importance of multi-model analysis rather than relying on any single methodology. Among models with highest confidence, EPV, EROIC, Markov DDM lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About SNDX?
9 of 13 models are currently active for SNDX. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates SNDX's intrinsic value at $1.31, implying -94.4% downside from the current price. See which stocks rank higher →
How Does SNDX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, SNDX ranks #132 by Quality of Company score. CirclFi's QOC score of 5.9/10 evaluates 32 fundamental signals. A score of 5.9 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a biopharma enterprise, Syndax Pharmaceuticals, Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating SNDX should weigh these sector-specific dynamics alongside our model-derived fair values.
Is SNDX a Value Trap?
CirclFi's Value Trap algorithm assigns SNDX a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Syndax Pharmaceuticals, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Syndax Pharmaceuticals, Inc.'s fundamental quality profile registers 5.9/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +98.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every SNDX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across SNDX's 9 active models, average confidence is 40%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad